Ohr Pharmaceutical
Ohr Pharmaceutical Inc. was a biotechnology company based in New York, focused on developing innovative therapeutics for serious ocular diseases, particularly wet age-related macular degeneration. Established in 2009, the company aimed to create non-invasive treatment alternatives to the standard intravitreal injections, leveraging sustained-release drug delivery systems and small molecule candidates targeting ocular inflammation and degeneration.
Despite initial promising clinical trials, Ohr faced challenges in advancing its lead product, OHR 102, and ultimately underwent a reverse merger with NeuBase Therapeutics in 2019. The transaction marked the end of Ohr's independent operations, transitioning its focus from ophthalmology to rare genetic disorders, with its historical assets and narrative largely absorbed by the newly formed entity.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.

